In an effort to protect newborn infants from the respiratory syncytial virus (RSV), the Centers for Disease Control and Prevention’s (CDC) advisory committee on immunizations voted to recommend the use of an RSV vaccine for pregnant women. The vaccine, known as Abrysvo and developed by Pfizer, is administered to pregnant women between weeks 32 and 36 of gestation. It works by inducing antibodies in the mothers, which are then passed on to their babies, providing them with protection during the first six months of life when they are most vulnerable to severe cases of RSV. Following the committee’s vote, the CDC promptly endorsed the vaccine, stating that it should be given to pregnant individuals during the recommended timeframe to optimize protection for their babies after birth.
In a statement, the CDC emphasized the importance of the RSV vaccine, calling it a “new tool” that can be used during the fall and winter to safeguard against serious RSV illness. CDC Director Mandy Cohen encouraged parents to consult with their doctors about the vaccine options available for protecting their infants. The CDC also projected that the RSV vaccine would become more widely accessible in the coming weeks. The anticipated cost of the vaccine is $295, but insurance coverage is expected if the CDC approves the committee’s recommendation.
Notably, Pfizer’s Abrysvo has already received approval for use in adults over the age of 60 to prevent lower respiratory tract diseases caused by RSV infection. This year, the availability of the RSV vaccine marks a significant milestone as it will aid in preventing RSV-related diseases in two populations at higher risk.
In addition to the RSV vaccine, the CDC recently endorsed a monoclonal antibody treatment from Sanofi called Beyfortus for infants under 8 months entering their first viral season and children between 8 and 19 months who are at an increased risk of severe illness and are entering their second viral season.
Last winter, many hospitals experienced overwhelming numbers of pediatric patients infected with RSV, underscoring the lack of preventative and treatment options for the virus. Prior to this year, there were no approved RSV vaccines, and only one treatment option—a monoclonal antibody reserved for high-risk infants.
As of 4:50 p.m., this information is up to date.
© 2023 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
